Prothena Corporation plc has released a corporate presentation detailing updates on its development pipeline focused on therapies for neurodegenerative and rare peripheral diseases linked to protein dysregulation. The presentation highlights the progress of prasinezumab, an anti-α-synuclein antibody for Parkinson's disease, which is set to enter Phase 3 clinical trials by the end of 2025 in collaboration with Roche. Additional updates include the Phase 3 CLEOPATTRA trial for coramitug (PRX004) targeting transthyretin amyloidosis, and ongoing Phase 2 and Phase 1 trials for investigational therapies targeting tau and other undisclosed targets in neurodegeneration. The company also outlines strategic collaborations with Bristol Myers Squibb, Novo Nordisk, and Roche. You can access the full presentation through the link below.